Studies new biomarkers to diagnose and track neuroendocrine tumors
Observes blood-based markers in adults with lung or digestive neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Key facts
- Where
- Rome, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04464122, who can take part
Where in Italy
- Andrea M IsidoriRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Roma La Sapienza
- Trial code
- NCT04464122
- Record updated
- 3 April 2025
- Original description
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.Read full original descriptionShow less
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
Inclusion: Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group); Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).
Exclusion: Severe chronic kidney disease (stage 4-5); Other non-neuroendocrine malignancies; Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease.